(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PARP inhibitors and beyond included a presentation by Dr. Johann De Bono regarding differences between DNA repair defect aberrations and the impact on patient management. Dr. De Bono started by highlighting that >20-30% of advanced prostate cancer patients have DNA repair defect mutations, including BRCA2, ATM, PALB2, CDK12, MMR genes, BRCA1 and other genes. According to Dr. De Bono, the percentage of mutations likely increases with endocrine treatment resistance. Specific to germline DNA repair defects, 8-18% of advanced prostate cancer patients have germline mutations, with interesting variations in geography such that men in New York City have more mutations compared to men in London, compared to men in Seattle. Dr. De Bono also notes that PARP inhibitors have received regulatory approval for select cases of advanced prostate cancer, including: